1
|
Zoellner A, Unterhalt M, Stilgenbauer S, Hübel K, Thieblemont C, Metzner B, Kluin-Nelemans H, Hiddemann W, Dreyling M, Hoster E. AUTOLOGOUS STEM CELL TRANSPLANTATION IN FIRST REMISSION SIGNIFICANTLY PROLONGS PROGRESSION-FREE AND OVERALL SURVIVAL IN MANTLE CELL LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.13_2629] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- A. Zoellner
- Department of Medicine III; University Hospital; LMU Munich Munich Germany
| | - M. Unterhalt
- Department of Medicine III; University Hospital; LMU Munich Munich Germany
| | - S. Stilgenbauer
- Department of Internal Medicine I; University Hospital of Homburg; Homburg Germany
| | - K. Hübel
- Department of Medicine I; University Hospital of Cologne; Cologne Germany
| | - C. Thieblemont
- Hemato-Oncology Department; Diderot University; Hôpital Saint-Louis Paris France
| | - B. Metzner
- Department of Hematology/Oncology; University Hospital Oldenburg; Oldenburg Germany
| | | | - W. Hiddemann
- Department of Medicine III; University Hospital; LMU Munich Munich Germany
| | - M. Dreyling
- Department of Medicine III; University Hospital; LMU Munich Munich Germany
| | - E. Hoster
- Department of Medicine III; University Hospital; LMU Munich Munich Germany
| |
Collapse
|
2
|
van Balkum M, Kluin-Nelemans H, van Hellemond JJ, van Genderen PJJ, Wismans PJ. Hypereosinophilia: a diagnostic challenge. Neth J Med 2018; 76:431-436. [PMID: 30569889] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Hypereosinophilia encompasses a broad differential diagnosis of atopy/allergic reactions, drug reactions, parasitic infections and paraneoplastic syndromes. Although mostly of limited clinical significance, hypereosinophilia can also be related to hematological malignancies. One has to be aware of the potential for secondary organ damage for example, in the case of hypereosinophilic syndrome. We present three cases with different underlying mechanisms of hypereosinophilia with a brief overview of causes, diagnostic work-up and treatment options.
Collapse
Affiliation(s)
- M van Balkum
- Harbour Hospital and Institute for Tropical Diseases, Rotterdam, the Netherlands (currently working at Albert Schweitzer Hospital, Rotterdam)
| | | | | | | | | |
Collapse
|
3
|
Maraldo M, Giusti F, van der Kaaij M, Henry-Amar M, Aleman B, Raemaekers J, Meijnders P, Moser E, Kluin-Nelemans H, Spina M, Ferme C, Fortpied C, Specht L. Cardiac Disease and Lifestyle Risk Factors Following Hodgkin Lymphoma: An EORTC Lymphoma Group and GELA Follow-Up Study. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.323] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
4
|
Aukema S, Hoster E, Rosenwald A, Canoni D, Rymkiewicz G, Thorns C, Hartmann S, Kluin-Nelemans H, Hermine O, Dreyling M, Klapper W. P53 BUT NOT SOX11 IHC HAS PROGNOSTIC VALUE INDEPENDENT OF MIPI AND KI-67 IN PROSPECTIVE TRIALS OF THE EUROPEAN-MCL NETWORK. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_129] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- S.M. Aukema
- Dept. of Pathology and Hematopathology Section and Lymph Node Registry; Christian Albrechts University of Kiel; Kiel Germany
| | - E. Hoster
- Department of Internal Medicine III; University Hospital Munich; Munich Germany
| | - A. Rosenwald
- Department of Pathology; University of Würzburg; Würzburg Germany
| | - D. Canoni
- Department of Pathology, Hôpital Necker; Assistance Publique Hôpitaux de Paris; Paris France
| | - G. Rymkiewicz
- Department of Pathology; The Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology; Warsaw Poland
| | - C. Thorns
- Department of Pathology; University Hospital Schleswig-Holstein, Lübeck; Lübeck Germany
| | - S. Hartmann
- Department of Pathology; University Hospital of Frankfurt; Frankfurt am Main Germany
| | - H.C. Kluin-Nelemans
- Department of Hematology; University Medical Center Groningen; Groningen Netherlands
| | - O. Hermine
- Department of Hematology, Hôpital Necker, Assistance Publique Hôpitaux de Paris; University Paris Descartes; Paris France
| | - M. Dreyling
- Department of Internal Medicine III; University Hospital Munich; Munich Germany
| | - W. Klapper
- Dept. of Pathology and Hematopathology Section and Lymph Node Registry; Christian Albrechts University of Kiel; Kiel Germany
| |
Collapse
|
5
|
Ribrag V, Feugier P, Doorduijn J, Delfau-Larue M, Hermine O, Kluin-Nelemans H, Dasilva M, Lopez-Hernandez A, Walewski J, Szymczyk M, Pott C, Homburg C, Van der Velden V, Gameiro P, Garcia-Sanz R, Ladetto M, van Krieken H, Cabeçadas J, Rymkiewicz G, Klapper W, Hoster E, Le Gouill S, Dreyling M. MCL-R2 ELDERLY: A PHASE III STUDY OF THE EUROPEAN MCL NETWORK
ASSESSING EFFICACY OF ALTERNATING IMMUNOCHEMOTHERAPY (R-CHOP / R-HAD) AND a RITUXIMAB-LENALIDOMIDE MAINTENANCE. Hematol Oncol 2017. [DOI: 10.1002/hon.2440_3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- V. Ribrag
- Hematology; Gustave Roussy Cancer Campus; Villejuif France
| | - P. Feugier
- Hematology; Hôpitaux De Brabois; Vandoeuvre-Les-Nancy France
| | - J. Doorduijn
- Hematology; Department of Hematology, Erasmus MC; Rotterdam Netherlands
| | - M. Delfau-Larue
- Hématologie et Immunologie Biologiques; GH Henri Mondor; Creteil France
| | - O. Hermine
- Hematology; Groupe Hospitalier : Hôpital Universitaire Necker-Enfants Malades; Paris France
| | - H. Kluin-Nelemans
- Department of Hematology; University Medical Center Groningen, University of Groningen; Groningen Netherlands
| | - M. Dasilva
- Serviço De Hematologia; Instituto Português De Oncologia De Lisboa; Lisbon Portugal
| | | | - J. Walewski
- Lymphoid Malignancy; Maria Sklodowska-Curie Institute - Oncology Center; Warszawa Poland
| | - M. Szymczyk
- Lymphoid Malignancy; Maria Sklodowska-Curie Institute - Oncology Center; Warszawa Poland
| | - C. Pott
- Klinisch-Experimentelle Hämatologie; Universitätsklinikum Schleswig-Holstein; Kiel Germany
| | - C. Homburg
- Laboratoriumhoofd Immunocytologie; Sanquin Diagnostiek; Amsterdam Netherlands
| | - V. Van der Velden
- Hematology; Department of Hematology, Erasmus MC; Rotterdam Netherlands
| | - P. Gameiro
- Biologia Molecular Laboratório De Hemato-Oncologia; Instituto Português De Oncologia De Lisboa; Lisbon Portugal
| | | | - M. Ladetto
- Hematology; Azienda Ospedaliera Nazionale SS.Antonio e Biagio e C. Arrigo; Alessandria Italy
| | - H. van Krieken
- Pathology; Radboud University Medical Center; Nijmegen Netherlands
| | - J. Cabeçadas
- Serviço De Anatomia Patológica; Instituto Português De Oncologia De Lisboa; Lisbon Portugal
| | - G. Rymkiewicz
- Lymphoid Malignancy; Maria Sklodowska-Curie Institute - Oncology Center; Warszawa Poland
| | - W. Klapper
- Institut Für Pathologie, Sektion Hämatopathologie und Lymphknotenregister; Universitätsklinikum Schleswig-Holstein, Campus Kiel; Kiel Germany
| | - E. Hoster
- Department of Medicine III; University Hospital of Munich; Munich Germany
| | - S. Le Gouill
- Service d'Hématologie; CHU de Nantes; Nantes France
| | - M. Dreyling
- Department of Medicine III; University Hospital of Munich; Munich Germany
| |
Collapse
|
6
|
Maraldo M, Giusti F, van der Kaaij M, Henry-Amar M, Aleman B, Raemaekers J, Meijnders P, Moser E, Kluin-Nelemans H, Spina M, Ferme C, Fortpied C, Specht L. CARDIAC DISEASE PREDICTION FOLLOWING HODGKIN LYMPHOMA: AN EORTC LYMPHOMA GROUP AND GELA FOLLOW-UP STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_34] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- M.V. Maraldo
- Department of Clinical Oncology; Rigshospitalet; Copenhagen Denmark
| | - F. Giusti
- Department of Statistics; EORTC Headquarters; Brussels Belgium
| | - M.A. van der Kaaij
- Department of Internal Medicine; VU University Medical Centre; Amsterdam Netherlands
| | - M. Henry-Amar
- Centre de Traitement des Données du Cancéropôle Nord-Ouest; Centre François Baclesse; Caen France
| | - B. Aleman
- Department of Radiation Oncology; the Netherlands Cancer Institute; Amsterdam Netherlands
| | - J. Raemaekers
- Department of Hematology; Radboud University Medical Center; Nijmegen Netherlands
| | - P. Meijnders
- Department of Radiation Oncology, Iridium Cancer Network; University of Antwerp; Antwerp Belgium
| | - E.C. Moser
- Department of Radiation Oncology; Champalimaud Cancer Centre; Lisbon Portugal
| | - H.C. Kluin-Nelemans
- Department of Hematology; University Medical Centre Groningen, University of Groningen; Groningen Netherlands
| | - M. Spina
- Division of Medical Oncology; National Cancer Institute; Aviano Italy
| | - C. Ferme
- Department of Hematology; Institut Gustave Roussy; Villejuif France
| | - C. Fortpied
- Department of Statistics; EORTC Headquarters; Brussels Belgium
| | - L. Specht
- Department of Clinical Oncology; Rigshospitalet; Copenhagen Denmark
| |
Collapse
|
7
|
Cheah C, George A, Giné E, Chiappella A, Kluin-Nelemans H, Jurczak W, Krawczyk K, Mocikova H, Klener P, Salek D, Walewski J, Szymczyk M, Smolej L, Auer R, Ritchie D, Arcaini L, Williams M, Dreyling M, Seymour J. Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network. Ann Oncol 2013; 24:2119-23. [DOI: 10.1093/annonc/mdt139] [Citation(s) in RCA: 82] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
8
|
Knol H, Mulder A, Bogchelman D, Kluin-Nelemans H, van der Zee A, Meijer K. P-002 Underlying bleeding disorders in patients are equally important in menorrhagia with and without gynaecological abnormalities. Thromb Res 2013. [DOI: 10.1016/s0049-3848(13)70048-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
9
|
Wiewel-Verschueren S, Knol H, Lisman T, Bogchelman D, Kluin-Nelemans H, van der Zee A, Mulder A, Meijer K. P-040 No increased fibrinolysis in women with menorrhagia. Thromb Res 2013. [DOI: 10.1016/s0049-3848(13)70086-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
10
|
Gotlib JR, Kluin-Nelemans H, Mauro MJ, Hermine O, Hexner EO, Lipton JH, Awan FT, Nikolova ZG, Gross SH, Dutreix C, Dharan B, George T, Horny P, Akin C, Hartmann K, Valent P, Reiter A. A global phase II, single-arm, open-label study to determine the efficacy of midostaurin in patients with aggressive systemic mastocytosis (ASM) or mast cell leukemia (MCL) with or without an associated hematologic clonal nonmast cell lineage disease (AHNMD). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.tps200] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
11
|
Knol H, Schultinge L, Erwich J, Veeger N, Kluin-Nelemans H, Meijer K. 0.10a Risk of PPH in women using therapeutic dosage of LMWH during pregnancy and puerperium. Thromb Res 2011. [DOI: 10.1016/s0049-3848(11)70052-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
12
|
|
13
|
Raemaekers J, Kluin-Nelemans H, Teodorovic I, Meerwaldt C, Noordijk E, Thomas J, Glabbeke MV, Henry-Amar M, Carde P. The achievements of the EORTC Lymphoma Group. European Organisation for Research and Treatment of Cancer. Eur J Cancer 2002; 38 Suppl 4:S107-13. [PMID: 11858975 DOI: 10.1016/s0959-8049(01)00446-4] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
From 1964 onwards, the EORTC Lymphoma Group has conducted seven consecutive randomised phase 3 trials on early stage Hodgkin's lymphoma aiming at increasing efficacy, while decreasing short- and long-term toxicity. Staging laparotomy is definitely abandoned and replaced by identification of prognostic subgroups based on pretreatment clinical characteristics. Event-free and overall survival significantly improved from about 50 and then 70%, in the early years, to over 80 and then 90% more recently. Radiotherapy fields have become more restricted, whereas chemotherapy has become standard. Longitudinal quality-of-life assessment has become an integral part of our studies. In advanced stages, overall outcome has improved as well with 6-year survival rates of over 80%. In aggressive types of NHL, the second generation chemotherapy schedule CHVmP-BV was superior to CHVmP. We could not show any advantage for intensification of upfront treatment with autologous stem cell transplantation.
Collapse
Affiliation(s)
- J Raemaekers
- Deptartment of Hematology, University Medical Centre Nijmegen, PO Box 9101, 6500 HB, Nijmegen, The Netherlands.
| | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Giphart-Gassler M, De Nooij-Van Dalen A, Van Buuren-Van Seggelen V, Morolli B, Lohman P, Kluin-Nelemans H. A search for novel tumour suppressor genes for adult acute leukaemia by allelotyping at sub-telomeric chromosomal regions. Mutat Res 1998; 400:409-19. [PMID: 9685700 DOI: 10.1016/s0027-5107(98)00022-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
A search was initiated towards the localization of novel mutated tumour suppressor genes that may be involved in adult leukaemia. For this purpose, we measured the occurrence of loss of heterozygosity (LOH) in nine patients with acute B-lineage leukaemia (ALL) and one with undifferentiated leukaemia (AUL). Eight leukaemias exhibited a diploid karyotype. For each patient, PCR products of 130 polymorphic microsatellite markers, located in subtelomeric areas of every autosomal chromosome arm were analysed to visualize LOH events resulting from reduplication of a single mutated chromosome or from mitotic recombination. These kinds of LOH events contribute most to LOH in model systems but cannot be detected by classical cytogenetic techniques. By comparing allelic PCR products in tumour cells with those in normal cells, LOH was found in tumour cells of one ALL patient at 9p which harbours the known p16INK4A tumour suppressor gene. In the AUL patient, however, LOH was detected at the telomeres of 4q and 21q, suggesting that these sites may contain novel tumour suppressor genes specifically involved in this form of leukaemia. In the DNA of tumour cells from eight out of 10 patients no LOH was detected. This is in contrast with the general assumption that LOH is a frequent phenomenon in ALL. However, some markers at telomeric regions of chromosomes were already homozygous in the control T-cells of several patients. For instance, we found in the DNA of control cells from one patient five consecutive microsatellites on 9p up to 9p43 which were homozygous and in three other patients homozygosity was observed in band 8q24, which includes the MYC gene. These observations indicate that LOH events already are present in non-cancerous putative stem cells and that mitotic recombination may be a very early event in leukaemogenesis.
Collapse
Affiliation(s)
- M Giphart-Gassler
- MGC Department of Radiation Genetics and Chemical Mutagenesis, Sylvius Laboratories, Leiden University Medical Center, Leiden, Netherlands.
| | | | | | | | | | | |
Collapse
|